Recent News

• 10.17.2026 - TransCon® CNP (navepegritide), administré une fois par semaine, reçoit un avis favorable du CHMP dans le traitement de l’achondroplasie chez l’enfant
• 10.17.2026 - TransCon® CNP (Navepegritid), einmal wöchentlich, erhält eine positive Bewertung des CHMP für die Behandlung von Achondroplasie bei Kindern
• 10.16.2026 - Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
• 10.06.2026 - Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
• 09.14.2026 - Ascendis Announces Planned $400 Million Share Repurchase Program
• 09.14.2026 - Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
• 09.09.2026 - First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
• 09.08.2026 - Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
• 09.07.2026 - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
• 08.31.2026 - Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

Recent Filings

• 10.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.14.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.08.2026 - 144 Report of proposed sale of securities